Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Ardelyx, Inc. (ARDX)

Pharmaceutical Preparations

https://www.ardelyx.com

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

34175 ARDENWOOD BLVD.
FREMONT, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/19/2014

Market Cap

1,369,013,820

Shares Outstanding

232,140,000

Weighted SO

232,137,709

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

BLRX --.--%

LXRX --.--%

MCRB --.--%

IBRX --.--%

ZURA --.--%

HEPA --.--%

AVRO --.--%

VSTM --.--%

Beta

0.8200

Last Div

0.0000

Range

3.16-10.13

Chg

-0.0650

Avg Vol

4575143

Mkt Cap

1369013820

Exch

NASDAQ

Country

US

Phone

510 745 1700

DCF Diff

19.2721

DCF

-9.6021

Div Yield

0.0000

P/S

6.5191

EV Multiple

-25.9386

P/FV

9.2798

Div Yield %

0.0000

P/E

-20.9384

PEG

-0.7328

Payout

0.0000

Current Ratio

4.2126

Quick Ratio

3.9923

Cash Ratio

0.6709

DSO

64.7287

DIO

169.0951

Op Cycle

233.8238

DPO

133.7543

CCC

100.0695

Gross Margin

0.8586

Op Margin

-0.2805

Pretax Margin

-0.3068

Net Margin

-0.3102

Eff Tax Rate

-0.0112

ROA

-0.1897

ROE

-0.3973

ROCE

-0.2096

NI/EBT

1.0112

EBT/EBIT

1.0939

EBIT/Rev

-0.2805

Debt Ratio

0.3022

D/E

0.7062

LT Debt/Cap

0.4055

Total Debt/Cap

0.4139

Int Coverage

-24.2370

CF/Debt

-0.8218

Equity Multi

2.3368

Rec Turnover

5.6389

Pay Turnover

2.7289

Inv Turnover

2.1585

FA Turnover

39.3257

Asset Turnover

0.6114

OCF/Share

-0.3637

FCF/Share

-0.3659

Cash/Share

0.7928

OCF/Sales

-0.4062

FCF/OCF

1.0061

CF Coverage

-0.8218

ST Coverage

-24.0296

CapEx Coverage

-164.6815

Div&CapEx Cov

-164.6815

P/BV

9.2798

P/B

9.2798

P/S

6.5191

P/E

-20.9384

P/FCF

-15.9516

P/OCF

-15.9901

P/CF

-15.9901

PEG

-0.7328

P/S

6.5191

EV Multiple

-25.9386

P/FV

9.2798

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 28, 14:36 ROSEN, A LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX GlobeNewswire Inc. Sep 24, 21:56 ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX GlobeNewswire Inc. Sep 22, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 14, 19:32 ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX GlobeNewswire Inc. Sep 10, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 05, 22:42 ARDX Lawsuit Reminder - Robbins LLP Encourages Ardelyx, Inc. Stockholders to Seek Counsel for Class Action Lawsuit GlobeNewswire Inc. Aug 30, 00:35 DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx GlobeNewswire Inc. Aug 27, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm GlobeNewswire Inc. Aug 18, 21:26 Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX Benzinga Jan 12, 12:00 Wedbush Maintains Outperform Rating for Ardelyx: Here's What You Need To Know GlobeNewswire Inc. Jan 12, 07:56 Ardelyx, Inc. Reports Employment Inducement Grants Benzinga Dec 18, 13:14 Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst PennyStocks Dec 05, 17:10 Penny Stocks To Buy Now? 5 Under $5 To Watch This Week PennyStocks Dec 01, 12:15 5 Hot Penny Stocks To Watch Today Benzinga Dec 01, 10:00 The Latest Analyst Ratings for Ardelyx PennyStocks Nov 21, 11:01 3 Top Penny Stocks To Watch Before Next Week PennyStocks Nov 17, 11:19 Penny Stocks To Buy? 4 Under $5 To Watch Right Now The Motley Fool Oct 31, 17:09 Why Ardelyx Stock Soared Today GlobeNewswire Inc. Oct 30, 17:42 Ardelyx, Inc. Reports Employment Inducement Grants

Revenue Product Segmentation